Na tej stronie
ZTS Klasa A Zoetis Inc. Class A Common Stock
NYSE · Pharmaceuticals · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026
$69,69
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$68,7852tyg. minimum
$148,7952tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$28.86B
P/E (TTM)
11.5
EPS (TTM)
$6.07
Przychody (TTM)
$9.52B
Twoje odznaki
Zakres 52 tyg.
$69–$149
Ocena Analityków
HOLD
Cena Docelowa
$96
P/E
11.5
ROE
64.4%
Marża Zysku Netto
27.5%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
ZTS Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$69.69
Kapitalizacja Rynkowa (MRQ)
$28.86B
P/E (TTM)
11.5
EPS (TTM)
$6.07
Przychody (TTM)
$9.52B
ROE (TTM)
64.4%
D/E Dług/Kapitał (MRQ)
2.9
Zakres 52 tyg.
$69–$149
ZTS Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O Zoetis Inc. Class A Common Stock Przegląd firmy z Wikipedii
Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses.
The firm is named Zoetis in allusion to the Greek-derived zoological term zoetic, meaning "pertaining to life". The company was owned by Pfizer until 2013.
History
1950s to 2000s
In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock.
In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo.
In 1988, the division was renamed Pfizer Animal Health.
In 1995, Pfizer acquired Norden Laboratories from GlaxoSmithKline for $1.45 billion, expanding its animal health division into small animal care, including pets.
Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003.
In April 2003, Pfizer acquired Pharmacia Corporation for $60 billion in stock. Pfizer absorbed its animal health assets, which included the legacy operations of The Upjohn Company, into Pfizer Animal Health.
In December 2006, Pfizer Animal Health acquired Embrex, which provides inoculations for poultry against various diseases, for $155 million.
In March 2008, Pfizer Animal Health acquired Catapult Genetics, a developer of livestock DNA tests and gene markers, and Bovigen, which markets DNA technology.
In April 2008, Pfizer Animal Health acquired vaccine products from Schering-Plough.
In June 2009, Pfizer Animal Health acquired Vetnex Animal Health from ICICI Bank.
In October 2009, Pfizer acquired Wyeth, including its subsidiary Fort Dodge Animal Health, which was added to Pfizer Animal Health. Some assets were sold to Boehringer Ingelheim to gain regulatory approval for the transaction.
In May 2010, Pfizer Animal Health acquired Microtek, a developer of aquaculture vaccines.
2010s-present
In January 2011, Pfizer Animal Health acquired Synbiotics, a developer of immunodiagnostic tests for companion and food production animals, for $20 million.
In February 2011, Pfizer acquired King Pharmaceuticals; its Alpharma subsidiary was integrated into Pfizer Animal Health.
In June 2012, Pfizer Animal Health was renamed Zoetis.
In February 2013, Zoetis became a public company via an initial public offering, raising $2.2 billion. Most of the money raised through the IPO was used to pay off existing Pfizer debt. In June 2013, Pfizer divested itself of its remaining shares in Zoetis.
In February 2015, the company acquired a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.
In July 2015, the company acquired KL Automation, a robotics company specializing in automation technology for poultry hatchery.
In November 2015, the company announced it would acquire Pharmaq, a developer of aquaculture treatments and diseases, for $765 million.
In August 2016, the company acquired Scandinavian Micro Biodevices for $80 million.
In April 2017, Zoetis acquired Ireland-based Nexvet, a company with a biologics focused technology and product candidate pipeline.
In July 2018, the company acquired Abaxis for $1.9 billion in cash.
In June 2022, Zoetis acquired Basepaws, a privately held genetics company.
In August 2022, the company acquired Newmetrica, a Scottish company that develops digital tools designed to measure health-related quality of life.
In September 2022, Zoetis acquired Jurox, which develops 150 medicines including Alfaxan.
In August 2023, the company opened a 1.4 million square foot facility on 145 acres in Lincoln, Nebraska.
In September 2023, Zoetis acquired Petmedix, a privately held Cambridge, UK-based company, to bring the benefits of species-specific antibody therapies to pet owners.
In December 2023, Zoetis acquired adivo, a German manufacturer of antibodies for pet medicine.
In October 2024, the company sold its medicated feed additive product portfolio and certain water-soluble products to Phibro Animal Health.
In February 2025, the United States Department of Agriculture granted Zoetis conditional approval to deploy its bird flu vaccine in poultry, after a bird flu outbreak had infected nearly 70 people in the USA, resulting in one death, with most cases occurring among farm workers exposed to infected poultry or cattle. In January 2025, the USDA announced plans to replenish its bird flu vaccine stockpile for poultry, aligning with the strain affecting commercial and wild bird populations, similar to efforts following major outbreaks in 2014 and 2015.
In November 2025, the company acquired Veterinary Pathology Group.
In March 2026, the company agreed to acquired the genomics business of Neogen.
In July 2026, the company agreed to acquire VitalRADS, a veterinary teleradiology platform.
Products
Zoetis' manufacturing network, includes 28 sites in 11 countries. Each facility is designed to meet chemical and infectious agent safety regulatory requirements. Many R&D operations are co-located with manufacturing sites, a collaboration that allows bringing new products to market faster.
Zoetis products include:
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaPharmaceuticals
pracownicy14 500
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$9.47B2016-12-31 → 2025-12-31
EPS$6.022016-12-31 → 2025-12-31
Wolny przepływ pieniężny$2.28B2016-12-31 → 2025-12-31
Marża netto27.5%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | ZTS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 11.5średnia z 5 lat ≈35.9 | ≈35.9 | 31.0 | Niedowartościowany | |
| P/S (TTM) | 3.0średnia z 5 lat ≈9.5 | ≈9.5 | · | · | |
| P/B (MRQ) | 9.2średnia z 5 lat ≈18.1 | ≈18.1 | · | · | |
| Cena / FCF (TTM) | 12.2średnia z 5 lat ≈45.7 | ≈45.7 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 10.0średnia z 5 lat ≈33.9 | ≈33.9 | · | · | |
| EV / Przychody (TTM) | 3.8 | · | · | · | |
| EV / FCF (TTM) | 15.3 | · | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 12.9średnia z 5 lat ≈180.4 | ≈180.4 | · | · | |
| PEG Ratio (Współczynnik PEG) | ≈1.0 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | ZTS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| EBITDA Margin (Marża EBITDA) | 5.1%średnia z 5 lat ≈5.6% | ≈5.6% | 8.3% | Słaby | |
| Marża przed opodatkowaniem (TTM) | 34.4%średnia z 5 lat ≈33.7% | ≈33.7% | 15.0% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | 27.5%średnia z 5 lat ≈27.0% | ≈27.0% | 10.4% | Najwyższa półka | |
| ROA (TTM) | 17.7%średnia z 5 lat ≈16.2% | ≈16.2% | 9.8% | Najwyższa półka | |
| ROE (TTM) | 64.4%średnia z 5 lat ≈52.6% | ≈52.6% | 25.3% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | ZTS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 2.9średnia z 5 lat ≈1.7 | ≈1.7 | 0.9 | Wysokie zadłużenie | |
| Wskaźnik bieżący (MRQ) | 3.1średnia z 5 lat ≈2.9 | ≈2.9 | 1.6 | Silna płynność | |
| Wskaźnik Szybkości (MRQ) | 1.6średnia z 5 lat ≈0.6 | ≈0.6 | 0.8 | Silna płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 2.9średnia z 5 lat ≈1.6 | ≈1.6 | 0.9 | Wysokie zadłużenie |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | ZTS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 2.3%średnia z 5 lat ≈7.3% | ≈7.3% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 5.4%średnia z 5 lat ≈6.7% | ≈6.7% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 7.2% | · | · | · | |
| EPS YoY | 10.1%średnia z 5 lat ≈12.2% | ≈12.2% | · | · | |
| Net Income YoY (Zysk Netto R/R) | 7.5%średnia z 5 lat ≈10.5% | ≈10.5% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 10.3%średnia z 5 lat ≈11.0% | ≈11.0% | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | 12.0% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 8.1%średnia z 5 lat ≈9.2% | ≈9.2% | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | 10.3% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | ZTS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.6średnia z 5 lat ≈0.6 | ≈0.6 | 0.5 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 1.1średnia z 5 lat ≈1.1 | ≈1.1 | 1.5 | Słaby | |
| Receivables Turnover (Rotacja należności) | 6.5średnia z 5 lat ≈6.9 | ≈6.9 | 5.6 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$652.9K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Zannualizowane wypłaty≈$2.12
CAGR dywidendy 5-letni≈20.1%
Seria wzrostów≈11
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Lip 20, 2026 | $0,53 | USD | ≈2.7% |
| Kwi 20, 2026 | $0,53 | USD | ≈1.7% |
| Sty 20, 2026 | $0,53 | USD | ≈1.6% |
| Paź 31, 2025 | $0,50 | USD | ≈1.4% |
| Lip 18, 2025 | $0,50 | USD | ≈1.3% |
| Kwi 21, 2025 | $0,50 | USD | ≈1.3% |
| Sty 21, 2025 | $0,50 | USD | ≈1.1% |
| Paź 31, 2024 | $0,43 | USD | ≈0.97% |
| Lip 18, 2024 | $0,43 | USD | ≈0.93% |
| Kwi 18, 2024 | $0,43 | USD | ≈1.1% |
| Sty 18, 2024 | $0,43 | USD | ≈0.82% |
| Paź 31, 2023 | $0,38 | USD | ≈0.96% |
| Lip 20, 2023 | $0,38 | USD | ≈0.84% |
| Kwi 20, 2023 | $0,38 | USD | ≈0.80% |
| Sty 19, 2023 | $0,38 | USD | ≈0.83% |
| Paź 31, 2022 | $0,33 | USD | ≈0.86% |
| Lip 20, 2022 | $0,33 | USD | ≈0.70% |
| Kwi 20, 2022 | $0,33 | USD | ≈0.61% |
| Sty 19, 2022 | $0,33 | USD | ≈0.54% |
| Paź 28, 2021 | $0,25 | USD | ≈0.47% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
2.5%
Następny raport
Lis 05, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 6, 2026 | $1.87 | $1.87 | -0.22% |
| 31 marca 2026 | $1.53 | $1.63 | -6.2% | |
| 31 grudnia 2025 | $1.48 | $1.42 | 4.5% | |
| 30 września 2025 | $1.70 | $1.64 | 3.8% | |
| 30 czerwca 2025 | $1.76 | $1.63 | 7.8% | |
| 31 marca 2025 | $1.48 | $1.41 | 5.2% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B | $6.26B | $5.83B | $5.31B | $4.89B | $4.76B | $4.79B | |
| Cost of Revenue | $2.67B | $2.72B | $2.56B | $2.45B | $2.30B | $2.06B | $1.99B | $1.91B | $1.77B | $1.67B | $1.74B | $1.72B | |
| SG&A Expense | $2.38B | $2.32B | $2.15B | $2.01B | $2.00B | $1.73B | $1.64B | $1.48B | $1.33B | $1.36B | $1.53B | $1.64B | |
| Interest Expense | $222M | $225M | $239M | $221M | $224M | $231M | $223M | $206M | $175M | $166M | $124M | $117M | |
| Other Non-op | $-6M | $-4M | $-2M | $14M | $-4M | $-5M | $0 | $15M | $1M | $2M | $5M | $-3M | |
| Pretax Income | $3.36B | $3.13B | $2.94B | $2.66B | $2.49B | $2.00B | $1.80B | $1.69B | $1.52B | $1.23B | $545M | $820M | |
| Income Tax | $687M | $637M | $596M | $545M | $454M | $360M | $301M | $266M | $663M | $409M | $206M | $233M | |
| Net Income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B | $1.50B | $1.43B | $864M | $821M | $339M | $583M | |
| EPS (Basic) | $6.03 | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 | $3.14 | $2.96 | $1.76 | $1.66 | $0.68 | $1.16 | |
| EPS (Diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | |
| Shares (Basic) | 443,443,000 | 454,200,000 | 461,172,000 | 468,891,000 | 474,348,000 | 475,502,000 | 478,128,000 | 483,063,000 | 489,918,000 | 495,715,000 | 499,707,000 | 501,055,000 | |
| Shares (Diluted) | 443,835,000 | 454,848,000 | 462,269,000 | 470,385,000 | 476,717,000 | 478,569,000 | 481,787,000 | 486,898,000 | 493,161,000 | 498,225,000 | 502,019,000 | 502,025,000 | |
| EBITDA | $487M | $497M | $491M | $465M | $448M | $441M | $412M | $308M | $242M | $240M | $199M | $204M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.45B | $1.99B | $2.04B | $3.58B | $3.48B | $3.60B | $1.93B | $1.60B | $1.56B | $727M | $1.15B | $882M | |
| Short-term Investments | $0 | · | · | · | · | · | $0 | $99M | $0 | · | · | · | |
| Receivables | $1.41B | $1.32B | $1.30B | $1.22B | $1.13B | $1.01B | $1.09B | $1.04B | $998M | $913M | $937M | $980M | |
| Inventory | $2.46B | $2.31B | $2.56B | $2.35B | $1.92B | $1.63B | $1.41B | $1.39B | $1.43B | $1.50B | $1.47B | $1.29B | |
| Other Current Assets | $450M | $377M | $434M | $365M | $389M | $366M | $318M | $271M | $228M | $248M | $201M | $205M | |
| Current Assets | $6.77B | $5.99B | $6.34B | $7.51B | $6.93B | $6.61B | $4.75B | $4.40B | $4.22B | $3.39B | $3.83B | $3.46B | |
| PP&E (Net) | $3.69B | $3.39B | $3.20B | $2.75B | $2.42B | $2.20B | $1.94B | $1.66B | $1.44B | $1.38B | $1.31B | $1.32B | |
| PP&E (Gross) | $6.61B | $6.03B | $5.80B | $5.05B | $4.49B | $4.15B | $3.68B | $3.26B | $2.91B | $2.74B | $2.52B | $2.46B | |
| Accum. Depreciation | $2.94B | $2.63B | $2.59B | $2.30B | $2.07B | $1.95B | $1.74B | $1.60B | $1.47B | $1.36B | $1.21B | $1.15B | |
| Goodwill | $2.77B | $2.72B | $2.76B | $2.75B | $2.68B | $2.69B | $2.59B | $2.52B | $1.51B | $1.48B | $1.46B | $976M | |
| Intangibles | $998M | $1.13B | $1.34B | $1.38B | $1.47B | $1.71B | $1.89B | $2.05B | $1.27B | $1.23B | $1.19B | $727M | |
| Other Non-current Assets | $327M | $250M | $206M | $147M | $111M | $106M | $98M | $94M | $75M | $73M | $49M | $48M | |
| Total Assets | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B | $13.61B | $11.54B | $10.78B | $8.59B | $7.65B | $7.91B | $6.59B | |
| Accounts Payable | $445M | $433M | $411M | $405M | $436M | $457M | $301M | $313M | $261M | $265M | $293M | $290M | |
| Accrued Liabilities | $852M | $746M | $683M | $682M | $710M | $556M | $543M | $487M | $432M | $464M | $676M | $475M | |
| Short-term Debt | $0 | $0 | $3M | $2M | $0 | $4M | $0 | $9M | $0 | $0 | $0 | $0 | |
| Current Liabilities | $2.17B | $3.41B | $1.89B | $3.17B | $1.80B | $2.17B | $1.81B | $1.22B | $1.09B | $1.12B | $1.78B | $1.09B | |
| Capital Leases | $197M | $174M | $188M | $186M | $151M | $163M | $164M | $0 | · | · | · | · | |
| Deferred Tax | $137M | $167M | $146M | $142M | $320M | $378M | $434M | $474M | $380M | $244M | $264M | $277M | |
| Other Non-current Liabilities | $250M | $222M | $237M | $217M | $239M | $270M | $229M | $187M | $201M | $248M | $251M | $207M | |
| Total Liabilities | $12.07B | $9.47B | $9.29B | $10.52B | $9.36B | $9.84B | $8.84B | $8.59B | $6.80B | $6.15B | $6.82B | $5.25B | |
| Long-term Debt | $9.04B | $6.57B | $6.56B | $7.90B | $6.59B | $7.20B | $6.45B | $6.44B | $4.95B | $4.47B | $4.86B | $3.62B | |
| Total Debt | $9.04B | $6.57B | $6.57B | $7.90B | $6.59B | $7.20B | $6.45B | $6.45B | $4.95B | $4.47B | $4.86B | · | |
| Common Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Paid-in Capital | $1.10B | $1.18B | $1.13B | $1.09B | $1.07B | $1.06B | $1.04B | $1.03B | $1.01B | $1.02B | $1.01B | $958M | |
| Retained Earnings | $13.80B | $11.97B | $10.29B | $8.67B | $7.19B | $5.66B | $4.43B | $3.27B | $2.11B | $1.48B | $876M | $709M | |
| Treasury Stock | $10.69B | $7.45B | $5.60B | $4.54B | $2.95B | $2.23B | $2.04B | $1.49B | $852M | $421M | $203M | $0 | |
| AOCI | $-804M | $-940M | $-839M | $-817M | $-764M | $-730M | $-726M | $-629M | $-505M | $-598M | $-622M | $-361M | |
| Stockholders' Equity | $3.42B | $4.77B | $5.00B | $4.41B | $4.54B | $3.77B | $2.71B | $2.19B | $1.79B | $1.50B | $1.07B | $1.31B | |
| Liabilities + Equity | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B | $13.61B | $11.54B | $10.78B | $8.59B | $7.65B | $7.91B | $6.59B | |
| Shares Outstanding | 424,927,535 | 448,473,073 | 458,367,358 | 463,808,059 | 472,574,090 | 475,317,751 | 475,528,210 | 479,562,326 | 486,130,461 | 492,855,297 | 497,400,113 | 501,327,524 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $487M | $497M | $491M | $465M | $448M | $441M | $412M | $308M | $242M | $240M | $199M | $204M | |
| Stock-based Comp | $83M | $74M | $60M | $62M | $58M | $59M | $67M | $53M | $44M | $37M | $43M | $32M | |
| Deferred Tax | $-52M | $-338M | $-61M | $-286M | $-80M | $-62M | $-79M | $-112M | $127M | $-55M | $-85M | $-49M | |
| Amort. of Intangibles | $157M | $170M | $185M | $193M | $204M | $230M | $237M | $157M | $100M | $95M | $64M | $63M | |
| Restructuring | $49M | $43M | $46M | $6M | $33M | $8M | $33M | $26M | $13M | $2M | $301M | $17M | |
| Other Non-cash | $-287M | $234M | $-481M | $-443M | $-250M | $50M | $-105M | $113M | $69M | $-330M | $168M | $-144M | |
| Operating Cash Flow | $2.90B | $2.95B | $2.35B | $1.91B | $2.21B | $2.13B | $1.79B | $1.79B | $1.35B | $713M | $664M | $626M | |
| CapEx | $621M | $655M | $732M | $586M | $477M | $453M | $460M | $338M | $224M | $216M | $224M | $180M | |
| Investing Cash Flow | $-748M | $-315M | $-777M | $-883M | $-458M | $-572M | $-504M | $-2.26B | $-270M | $-214M | $-1.11B | $-187M | |
| Net Debt Issued | $-1.35B | $0 | $-1.35B | $0 | $-600M | $-500M | $0 | $0 | $-750M | $-400M | · | · | |
| Stock Repurchased | $3.23B | $1.86B | $1.09B | $1.59B | $743M | $250M | $626M | $698M | $500M | $300M | $203M | $0 | |
| Net Stock Activity | $-3.23B | $-1.86B | $-1.09B | $-1.59B | $-743M | $-250M | $-626M | $-698M | $-500M | $-300M | $-203M | · | |
| Financing Cash Flow | $-1.87B | $-2.66B | $-3.11B | $-904M | $-1.86B | $123M | $-951M | $533M | $-251M | $-903M | $755M | $-154M | |
| Net Change in Cash | $325M | $-54M | $-1.54B | $96M | $-119M | $1.67B | $332M | $38M | $837M | $-427M | $272M | $272M | |
| Taxes Paid | $715M | $892M | $754M | $638M | $548M | $418M | $418M | $336M | $455M | $408M | $224M | $278M | |
| Free Cash Flow | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B | $1.67B | $1.33B | $1.45B | $1.12B | $497M | $440M | $446M | |
| Levered FCF | $2.11B | $2.12B | $1.43B | $1.15B | $1.55B | $1.48B | $1.15B | $1.28B | $1.02B | $386M | $363M | $362M |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% | 7.1% | 12.2% | |
| Pretax Margin | 35.5% | 33.9% | 34.4% | 32.9% | 32.0% | 29.9% | 28.8% | 29.0% | 28.7% | 25.1% | 11.4% | 17.1% | |
| EBITDA Margin | 5.1% | 5.4% | 5.8% | 5.8% | 5.8% | 6.6% | 6.6% | 5.3% | 4.6% | 4.9% | 4.2% | 4.3% | |
| ROA | 18.0% | 17.4% | 16.1% | 14.7% | 14.8% | 13.0% | 13.4% | 14.7% | 10.6% | 10.5% | 4.7% | · | |
| ROE | 66.0% | 50.9% | 49.9% | 47.2% | 49.0% | 50.6% | 58.6% | 66.4% | 52.9% | 64.3% | 28.5% | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.0 | 1.8 | 3.4 | 2.4 | 3.9 | 3.0 | 2.6 | 3.6 | 3.9 | 3.0 | 2.2 | · | |
| Quick Ratio | 0.7 | 0.4 | 0.7 | 0.4 | 0.6 | 0.5 | 0.6 | 0.9 | 2.3 | 1.5 | 1.2 | · | |
| Debt / Equity | 2.7 | 1.4 | 1.3 | 1.8 | 1.5 | 1.9 | 2.4 | 3.0 | 2.8 | 3.0 | 4.6 | · | |
| LT Debt / Equity | 2.7 | 1.1 | 1.3 | 1.5 | 1.5 | 1.7 | 2.2 | 2.9 | 2.8 | 3.0 | 4.2 | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | · | |
| Inventory Turnover | 1.1 | 1.1 | 1.0 | 1.1 | 1.3 | 1.4 | 1.4 | 1.4 | 1.2 | 1.1 | 1.3 | · | |
| Receivables Turnover | 6.5 | 7.1 | 6.8 | 6.9 | 7.2 | 6.4 | 5.9 | 5.7 | 5.6 | 5.3 | 5.0 | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.84 | $10.64 | $10.90 | $9.50 | $9.61 | $7.93 | $5.69 | $4.56 | $3.64 | $3.02 | $2.15 | · | |
| Revenue / Share | $21.33 | $20.35 | $18.48 | $17.18 | $16.31 | $13.95 | $12.99 | $11.96 | $10.76 | $9.81 | $9.49 | $9.53 | |
| Cash Flow / Share | $6.54 | $6.49 | $5.09 | $4.06 | $4.64 | $4.44 | $3.73 | $3.68 | $2.73 | $1.43 | $1.32 | $1.25 | |
| Cash / Share | · | · | · | · | · | · | · | · | $3.22 | $1.48 | $2.32 | · | |
| Dividend Paid / Share | $2.03 | $1.80 | $1.56 | $1.35 | $1.07 | $0.85 | $0.69 | $0.54 | $0.44 | $0.39 | $0.34 | $0.30 | |
| EPS (TTM) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.3% | 8.3% | 5.7% | 3.9% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.4% | 6.0% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 10.1% | 7.9% | 12.9% | 5.1% | 24.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 10.3% | 8.6% | 14.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 12.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 7.5% | 6.1% | 10.9% | 3.8% | 24.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 8.1% | 6.9% | 12.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 10.3% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B | $6.26B | $5.83B | $5.31B | $4.89B | $4.76B | $4.79B | |
| Net Income TTM | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B | $1.50B | $1.43B | $864M | $821M | $339M | $583M | |
| Market Cap | $53.46B | $73.07B | $90.47B | $67.97B | $115.32B | $78.67B | $62.94B | $41.02B | $35.02B | $26.38B | $23.84B | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $38.41B | $30.12B | $27.54B | · | |
| P/E | 20.9 | 29.8 | 38.9 | 32.6 | 57.1 | 48.4 | 42.6 | 29.2 | 41.2 | 32.4 | 70.5 | 37.1 | |
| P/S | 5.6 | 7.9 | 10.6 | 8.4 | 14.8 | 11.8 | 10.1 | 7.0 | 6.6 | 5.4 | 5.0 | · | |
| P/B | 16.1 | 15.3 | 18.1 | 15.4 | 25.4 | 20.9 | 23.2 | 18.8 | 19.8 | 17.7 | 22.3 | · | |
| P / Tangible Book | · | 79.5 | 100.5 | 243.6 | 298.0 | · | · | · | · | · | · | · | |
| P / Cash Flow | 18.4 | 24.7 | 38.4 | 35.5 | 52.1 | 37.0 | 35.1 | 22.9 | 26.0 | 37.0 | 35.9 | · | |
| P / FCF | 23.4 | 31.8 | 55.8 | 51.3 | 66.4 | 47.0 | 47.1 | 28.3 | 31.2 | 53.1 | 54.2 | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 158.7 | 125.5 | 138.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 34.2 | 60.6 | 62.6 | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 7.2 | 6.2 | 5.8 | · | |
| Earnings Yield | 4.8% | 3.4% | 2.6% | 3.1% | 1.8% | 2.1% | 2.4% | 3.4% | 2.4% | 3.1% | 1.4% | 2.7% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.47B | $2.26B | $2.39B | $2.40B | $2.47B | $2.20B | $2.32B | $2.39B | $2.36B | $2.19B | $2.21B | $2.15B | $2.18B | $2.00B | $2.04B | $2.00B | |
| Cost of Revenue | $673M | $641M | $712M | $683M | $664M | $618M | $707M | $701M | $668M | $643M | $728M | $638M | $607M | $588M | $653M | $607M | |
| SG&A Expense | $592M | $588M | $619M | $579M | $614M | $574M | $625M | $565M | $581M | $547M | $565M | $525M | $556M | $505M | $514M | $501M | |
| Interest Expense | $61M | $62M | $57M | $58M | $53M | $54M | $51M | $57M | $59M | $58M | $59M | $59M | $58M | $63M | $62M | $53M | |
| Other Non-op | $-2M | $-1M | $-8M | $0 | $-1M | $3M | $1M | $-2M | $2M | $-5M | $5M | $-4M | $2M | $-5M | $6M | $1M | |
| Pretax Income | $866M | $758M | $761M | $887M | $912M | $773M | $732M | $874M | $780M | $747M | $650M | $717M | $872M | $697M | $592M | $667M | |
| Income Tax | $175M | $157M | $158M | $166M | $186M | $171M | $151M | $182M | $156M | $148M | $127M | $121M | $202M | $146M | $132M | $139M | |
| Net Income | $691M | $601M | $603M | $721M | $726M | $602M | $581M | $682M | $624M | $599M | $525M | $596M | $671M | $552M | $461M | $529M | |
| EPS (Basic) | $1.65 | $1.42 | $1.38 | $1.63 | $1.63 | $1.34 | $1.28 | $1.51 | $1.37 | $1.31 | $1.15 | $1.29 | $1.45 | $1.19 | $0.99 | $1.13 | |
| EPS (Diluted) | $1.65 | $1.42 | $1.37 | $1.63 | $1.63 | $1.34 | $1.29 | $1.50 | $1.37 | $1.31 | $1.14 | $1.29 | $1.45 | $1.19 | $0.98 | $1.13 | |
| Shares (Basic) | 417,600,000 | 422,100,000 | · | 442,900,000 | 445,100,000 | 447,600,000 | · | 452,900,000 | 455,500,000 | 458,000,000 | · | 460,300,000 | 461,900,000 | 463,500,000 | · | 467,800,000 | |
| Shares (Diluted) | 417,700,000 | 422,400,000 | · | 443,200,000 | 445,500,000 | 448,000,000 | · | 453,500,000 | 456,000,000 | 458,800,000 | · | 461,400,000 | 462,900,000 | 464,600,000 | · | 469,100,000 | |
| EBITDA | $119M | $119M | · | $124M | $123M | $119M | · | $121M | $127M | $126M | · | $124M | $121M | $120M | · | $115M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.48B | $1.94B | · | $2.08B | $1.44B | $1.72B | · | $1.71B | $1.57B | $1.98B | · | $1.75B | $1.72B | $2.11B | · | $2.51B | |
| Short-term Investments | $200M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $1.57B | $1.51B | $1.59B | $1.54B | $1.54B | $1.36B | $1.32B | $1.41B | $1.38B | $1.29B | · | $1.26B | $1.32B | $1.19B | · | $1.19B | |
| Inventory | $2.57B | $2.55B | $2.43B | $2.46B | $2.44B | $2.37B | $2.31B | $2.42B | $2.45B | $2.65B | · | $2.74B | $2.70B | $2.56B | · | $2.30B | |
| Other Current Assets | $535M | $477M | $436M | $493M | $509M | $430M | $377M | $427M | $467M | $440M | · | $467M | $443M | $411M | · | $552M | |
| Current Assets | $6.36B | $6.47B | $6.77B | $6.58B | $5.92B | $5.88B | $5.99B | $6.28B | $6.20B | $6.36B | · | $6.22B | $6.18B | $6.27B | · | $6.55B | |
| PP&E (Net) | $3.76B | $3.72B | $3.68B | $3.60B | $3.54B | $3.44B | $3.39B | $3.30B | $3.20B | $3.25B | · | $3.09B | $3.01B | $2.91B | · | $2.62B | |
| PP&E (Gross) | · | · | $6.61B | · | · | · | $6.03B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.07B | $3.00B | $2.92B | $2.87B | $2.80B | $2.70B | $2.63B | $2.66B | $2.59B | $2.67B | · | $2.53B | $2.45B | $2.37B | · | $2.23B | |
| Goodwill | $2.77B | $2.78B | $2.77B | $2.76B | $2.76B | $2.72B | $2.72B | $2.74B | $2.74B | $2.76B | $2.76B | $2.76B | $2.71B | $2.74B | $2.75B | $2.69B | |
| Intangibles | $918M | $959M | $998M | $1.04B | $1.07B | $1.08B | $1.13B | $1.19B | $1.23B | $1.29B | · | $1.40B | $1.25B | $1.31B | · | $1.32B | |
| Other Non-current Assets | $384M | $351M | $328M | $293M | $267M | $232M | $250M | $215M | $210M | $227M | · | $216M | $173M | $143M | · | $161M | |
| Total Assets | $15.08B | $15.15B | $15.47B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B | $14.16B | $14.35B | · | $14.11B | $13.75B | $13.75B | · | $13.67B | |
| Accounts Payable | $452M | $507M | $487M | $410M | $508M | $420M | $433M | $404M | $420M | $405M | · | $388M | $464M | $424M | · | $373M | |
| Accrued Liabilities | · | · | $852M | · | · | · | $746M | · | · | · | · | · | · | · | · | · | |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $24M | · | $2M | $2M | $3M | · | $3M | |
| Current Liabilities | $2.06B | $2.05B | $2.23B | $1.81B | $3.37B | $3.38B | $3.41B | $1.70B | $1.80B | $1.91B | · | $1.61B | $1.77B | $1.92B | · | $2.88B | |
| Capital Leases | $190M | $193M | $196M | $204M | $210M | $173M | $174M | $181M | $181M | $184M | · | $191M | $188M | $180M | · | $186M | |
| Deferred Tax | $122M | $130M | $139M | $147M | $156M | $161M | $167M | $172M | $175M | $136M | · | $160M | $121M | $131M | · | $256M | |
| Other Non-current Liabilities | $220M | $219M | $248M | $264M | $274M | $220M | $222M | $220M | $222M | $228M | · | $259M | $217M | $216M | · | $239M | |
| Total Liabilities | $11.93B | $11.92B | $12.14B | $9.76B | $9.50B | $9.44B | $9.47B | $9.12B | $9.21B | $9.30B | · | $9.03B | $9.13B | $9.26B | · | $9.01B | |
| Long-term Debt | · | · | $9.04B | $7.07B | $6.58B | $6.58B | $6.57B | · | · | · | · | $6.55B | $6.55B | $6.56B | · | $6.56B | |
| Total Debt | $9.05B | $9.04B | · | $7.07B | $6.58B | $6.58B | · | $6.57B | $6.56B | $6.59B | · | $6.55B | $6.56B | $6.56B | · | $6.56B | |
| Common Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $5M | $5M | $5M | · | $5M | |
| Paid-in Capital | $1.13B | $1.10B | $1.10B | $1.22B | $1.20B | $1.18B | $1.18B | $1.16B | $1.15B | $1.13B | · | $1.12B | $1.10B | $1.08B | · | $1.07B | |
| Retained Earnings | $14.65B | $14.18B | $13.74B | $13.59B | $12.87B | $12.38B | $11.97B | $11.81B | $11.12B | $10.70B | · | $10.14B | $9.54B | $9.04B | · | $8.53B | |
| Treasury Stock | $11.85B | $11.29B | $10.69B | $8.61B | $8.23B | $7.89B | $7.45B | $6.89B | $6.46B | $5.93B | · | $5.37B | $5.13B | $4.81B | · | $4.14B | |
| AOCI | $-796M | $-772M | $-834M | $-818M | $-877M | $-1.02B | $-940M | $-851M | $-845M | $-841M | · | $-814M | $-895M | $-828M | · | $-809M | |
| Stockholders' Equity | $3.15B | $3.23B | $3.33B | $5.40B | $4.98B | $4.66B | $4.77B | $5.23B | $4.97B | $5.06B | · | $5.08B | $4.62B | $4.49B | · | $4.66B | |
| Liabilities + Equity | $15.08B | $15.15B | $15.47B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B | $14.16B | $14.35B | · | $14.11B | $13.75B | $13.75B | · | $13.67B | |
| Shares Outstanding | 414,154,046 | 420,348,495 | 424,927,535 | 441,464,339 | 443,945,593 | 446,040,205 | 448,473,073 | 451,549,789 | 453,812,361 | 456,947,205 | · | 459,524,713 | 460,750,652 | 462,495,343 | · | 466,442,095 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $119M | $119M | $121M | $124M | $124M | $119M | $123M | $121M | $127M | $126M | $126M | $124M | $121M | $120M | $119M | $115M | |
| Stock-based Comp | $26M | $25M | $22M | $22M | $22M | $17M | $19M | $18M | $19M | $18M | $17M | $17M | $17M | $9M | $16M | $15M | |
| Deferred Tax | $-33M | $34M | $-48M | $-16M | $-7M | $14M | $-152M | $-42M | $-101M | $-43M | $-21M | $-14M | $-34M | $8M | $-176M | $-34M | |
| Amort. of Intangibles | $38M | $39M | $38M | $39M | $40M | $40M | $42M | $42M | $42M | $44M | $44M | $46M | $48M | $47M | $46M | $48M | |
| Restructuring | $75M | $20M | $16M | $4M | · | · | $-3M | $-2M | $37M | $11M | $8M | $13M | $5M | $20M | $1M | · | |
| Other Non-cash | · | $-378M | · | · | · | $-199M | · | · | · | $-105M | · | · | · | $-140M | · | · | |
| Operating Cash Flow | $655M | $401M | $893M | $938M | $486M | $515M | $905M | $951M | $502M | $595M | $897M | $724M | $183M | $549M | $741M | $526M | |
| CapEx | $117M | $110M | $161M | $133M | $178M | $178M | $216M | $167M | $132M | $140M | $198M | $145M | $166M | $223M | $171M | $154M | |
| Investing Cash Flow | $-300M | $-87M | $-166M | $-160M | $-247M | $-203M | $126M | $-178M | $-132M | $-131M | $-210M | $-271M | $-80M | $-216M | $-438M | $-124M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-1.35B | · | · | |
| Stock Repurchased | $584M | $606M | $2.06B | $394M | $338M | $443M | $553M | $433M | $533M | $339M | $235M | $250M | $324M | $283M | $405M | $377M | |
| Net Stock Activity | · | $-606M | · | · | · | $-443M | · | · | · | $-339M | · | · | · | $-283M | · | · | |
| Financing Cash Flow | $-813M | $-840M | $-495M | $-134M | $-564M | $-677M | $-745M | $-628M | $-763M | $-524M | $-397M | $-416M | $-494M | $-1.80B | $780M | $-529M | |
| Net Change in Cash | $-465M | $-509M | $228M | $649M | $-286M | $-332M | $273M | $140M | $-401M | $-66M | $287M | $37M | $-392M | $-1.47B | $1.07B | $-145M | |
| Taxes Paid | $380M | $50M | $133M | $107M | $428M | $60M | $235M | $176M | $422M | $59M | $168M | $128M | $438M | $20M | $167M | $155M | |
| Free Cash Flow | · | $291M | · | · | · | $438M | · | · | · | $455M | · | · | · | $326M | · | · | |
| Levered FCF | · | $242M | · | · | · | $396M | · | · | · | $408M | · | · | · | $276M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 28.0% | 26.6% | · | 30.0% | 29.2% | 28.4% | · | 28.6% | 26.4% | 27.4% | · | 27.7% | 30.8% | 27.6% | · | 26.4% | |
| Pretax Margin | 35.1% | 33.5% | · | 37.0% | 36.7% | 36.5% | · | 36.6% | 33.0% | 34.1% | · | 33.3% | 40.0% | 34.8% | · | 33.3% | |
| EBITDA Margin | 4.8% | 5.3% | · | 5.2% | 5.0% | 5.4% | · | 5.1% | 5.4% | 5.8% | · | 5.8% | 5.5% | 6.0% | · | 5.7% | |
| ROA | 4.7% | 4.1% | · | 4.9% | 5.0% | 4.4% | · | 4.8% | 4.5% | 4.3% | · | 4.3% | 4.9% | 4.0% | · | 3.9% | |
| ROE | 17.0% | 15.2% | · | 13.6% | 14.4% | 13.0% | · | 13.2% | 13.0% | 12.5% | · | 12.2% | 14.6% | 12.1% | · | 11.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.2 | · | 3.6 | 1.8 | 1.7 | · | 3.7 | 3.5 | 3.3 | · | 3.9 | 3.5 | 3.3 | · | 2.3 | |
| Quick Ratio | 1.6 | 1.7 | · | 2.0 | 0.9 | 0.9 | · | 1.8 | 1.6 | 1.7 | · | 1.9 | 1.7 | 1.7 | · | 1.3 | |
| Debt / Equity | 2.9 | 2.8 | · | 1.3 | 1.3 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.5 | · | 1.4 | |
| LT Debt / Equity | 2.9 | 2.8 | · | 1.3 | 1.1 | 1.1 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.5 | · | 1.1 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.3 | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.6 | 1.6 | · | 1.6 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.8 | · | 1.8 | 1.7 | 1.7 | · | 1.7 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.60 | $7.69 | · | $12.23 | $11.21 | $10.44 | · | $11.59 | $10.94 | $11.07 | · | $11.05 | $10.04 | $9.72 | · | $10.00 | |
| Revenue / Share | $5.91 | $5.36 | · | $5.42 | $5.52 | $4.96 | · | $5.27 | $5.18 | $4.77 | · | $4.66 | $4.71 | $4.30 | · | $4.27 | |
| Cash Flow / Share | · | $0.95 | · | · | · | $1.31 | · | · | · | $1.30 | · | · | · | $1.18 | · | · | |
| Cash / Share | $3.56 | $4.62 | · | $4.72 | $3.23 | $3.86 | · | $3.80 | $3.47 | $4.32 | · | $3.82 | $3.73 | $4.56 | · | $5.37 | |
| Dividend / Share | $0.53 | $0.53 | · | $0.00 | $0.50 | $0.50 | · | $0.00 | $0.43 | $0.43 | · | $0.00 | $0.38 | $0.38 | · | $0.00 | |
| EPS (TTM) | $6.07 | $6.05 | · | $5.89 | $5.76 | $5.50 | · | $5.32 | $5.11 | $5.19 | · | $4.91 | $4.75 | $4.42 | · | $4.38 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.52B | $9.52B | · | $9.39B | $9.38B | $9.26B | · | $9.15B | $8.91B | $8.73B | · | $8.37B | $8.22B | $8.09B | · | $8.01B | |
| Net Income TTM | $2.62B | $2.65B | · | $2.63B | $2.59B | $2.49B | · | $2.43B | $2.34B | $2.39B | · | $2.28B | $2.21B | $2.07B | · | $2.07B | |
| Market Cap | $29.76B | $49.69B | · | $64.60B | $69.23B | $73.44B | · | $88.22B | $78.67B | $77.32B | · | $79.95B | $79.35B | $76.98B | · | $69.17B | |
| Enterprise Value | $37.13B | $56.79B | · | $69.58B | $74.38B | $78.30B | · | $93.08B | $83.66B | $81.93B | · | $84.75B | $84.19B | $81.43B | · | $73.22B | |
| P/E | 11.8 | 19.5 | · | 24.8 | 27.1 | 29.9 | · | 36.7 | 33.9 | 32.6 | · | 35.4 | 36.3 | 37.7 | · | 33.9 | |
| P/S | 3.1 | 5.2 | · | 6.9 | 7.4 | 7.9 | · | 9.6 | 8.8 | 8.9 | · | 9.6 | 9.7 | 9.5 | · | 8.6 | |
| P/B | 9.5 | 15.4 | · | 12.0 | 13.9 | 15.8 | · | 16.9 | 15.8 | 15.3 | · | 15.7 | 17.2 | 17.1 | · | 14.8 | |
| P / Tangible Book | · | · | · | 40.5 | 60.5 | 85.7 | · | 67.7 | 78.6 | 77.0 | · | 87.1 | 120.4 | 174.2 | · | 106.1 | |
| P / Cash Flow | · | 123.9 | · | · | · | 125.1 | · | · | · | 129.9 | · | · | · | 140.2 | · | · | |
| EV / Revenue | 3.9 | 6.0 | · | 7.4 | 7.9 | 8.5 | · | 10.2 | 9.4 | 9.4 | · | 10.1 | 10.2 | 10.1 | · | 9.1 | |
| Earnings Yield | 8.5% | 5.1% | · | 4.0% | 3.7% | 3.3% | · | 2.7% | 2.9% | 3.1% | · | 2.8% | 2.8% | 2.7% | · | 2.9% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Zysk netto | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| Rozwodniony EPS | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 2.7 | 1.4 | 1.3 | 1.8 | 1.5 |
| Wskaźnik bieżący | 3.0 | 1.8 | 3.4 | 2.4 | 3.9 |
| Wskaźnik Szybkości | 0.7 | 0.4 | 0.7 | 0.4 | 0.6 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B |
Właściciele instytucjonalni (13F) 1 578 emitentów · $35.8B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
1 578
Wartość posiadanych akcji
$35.8B
Nowe pozycje
170
Zamknięte pozycje
318
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 170 (-31 vs poprzedni kw.) | 318 (+136 vs poprzedni kw.) | 521 (-88 vs poprzedni kw.) | 585 (-42 vs poprzedni kw.) | -6.7M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6 011 802 148 | 47 780 974 | 16,82% | Akcje |
| BlackRock, Inc. | $2 833 452 809 | 39 430 181 | 7,93% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 870 370 930 | 26 027 984 | 5,23% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 714 611 578 | 23 860 445 | 4,80% | Akcje |
| STATE STREET CORP | $1 413 322 575 | 19 667 723 | 3,95% | Akcje |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1 142 064 009 | 15 892 903 | 3,19% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $951 789 721 | 13 289 622 | 2,66% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $677 201 094 | 9 423 895 | 1,89% | Akcje |
| MORGAN STANLEY | $638 034 469 | 8 878 849 | 1,78% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $519 929 070 | 4 398 351 | 1,45% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $471 698 956 | 6 592 578 | 1,32% | Akcje |
| JANUS HENDERSON GROUP PLC | $437 568 419 | 3 701 747 | 1,22% | Akcje |
| DEUTSCHE BANK AG\ | $420 505 821 | 5 851 737 | 1,18% | Akcje |
| NORTHERN TRUST CORP | $398 264 934 | 5 542 234 | 1,11% | Akcje |
| Invesco Ltd. | $396 884 095 | 5 523 018 | 1,11% | Akcje |
| FIL Ltd | $386 734 926 | 5 381 783 | 1,08% | Akcje |
| NORGES BANK | $337 012 405 | 4 689 847 | 0,94% | Akcje |
| VAN ECK ASSOCIATES CORP | $305 558 780 | 4 252 140 | 0,85% | Akcje |
| FLOSSBACH VON STORCH SE | $302 600 879 | 4 210 978 | 0,85% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $287 726 761 | 4 003 981 | 0,80% | Akcje |
| Amundi | $286 622 090 | 3 988 618 | 0,80% | Akcje |
| BANK OF AMERICA CORP /DE/ | $282 045 207 | 3 924 926 | 0,79% | Akcje |
| UBS Group AG | $261 803 299 | 3 643 241 | 0,73% | Akcje |
| Legal & General Group Plc | $256 352 499 | 3 567 388 | 0,72% | Akcje |
| Diamond Hill Capital Management, LLC (Investment Advisor) | $255 637 351 | 3 557 436 | 0,72% | Akcje |
| CIBC Private Wealth Group LLC | $246 008 713 | 1 681 306 | 0,69% | Akcje |
| Bank of New York Mellon Corp | $238 741 846 | 3 322 319 | 0,67% | Akcje |
| GOLDMAN SACHS GROUP INC | $229 937 577 | 3 199 799 | 0,64% | Akcje |
| CITADEL ADVISORS LLC | $229 108 579 | 3 188 263 | 0,64% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $225 456 582 | 3 137 442 | 0,63% | Akcje |
| JPMORGAN CHASE & CO | $192 268 534 | 2 624 825 | 0,54% | Akcje |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $173 617 784 | 2 416 056 | 0,49% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $170 008 975 | 2 365 836 | 0,48% | Akcje |
| Ruane, Cunniff & Goldfarb L.P. | $169 108 138 | 2 353 300 | 0,47% | Akcje |
| BARCLAYS PLC | $165 474 682 | 2 302 737 | 0,46% | Akcje |
| Qube Research & Technologies Ltd | $163 792 869 | 2 279 333 | 0,46% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $156 216 242 | 2 173 278 | 0,44% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $152 540 744 | 2 122 749 | 0,43% | Akcje |
| JANE STREET GROUP, LLC | $144 534 676 | 2 011 337 | 0,40% | Akcje |
| BRANDES INVESTMENT PARTNERS, LP | $138 737 455 | 1 930 651 | 0,39% | Akcje |
| HSBC HOLDINGS PLC | $132 131 854 | 1 839 811 | 0,37% | Akcje |
| BLS Capital Fondsmaeglerselskab A/S | $131 538 868 | 1 830 488 | 0,37% | Akcje |
| ROYAL BANK OF CANADA | $131 385 000 | 1 828 326 | 0,37% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $130 336 722 | 1 813 759 | 0,36% | Akcje |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $130 169 165 | 1 864 087 | 0,36% | Akcje |
| WELLS FARGO & COMPANY/MN | $130 014 751 | 1 809 278 | 0,36% | Akcje |
| Man Group plc | $129 707 516 | 1 805 003 | 0,36% | Akcje |
| Nuveen, LLC | $129 322 602 | 1 799 647 | 0,36% | Akcje |
| BANQUE PICTET & CIE SA | $128 888 455 | 1 793 605 | 0,36% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $125 134 922 | 1 741 371 | 0,35% | Akcje |
Aktywiści i właściciele 5%+ 2 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Pershing Square Capital Management, L.P., PS Management GP, LLC, William A. Ackman ×7 zgłoszenia | 8 lipca 2016 | · | Pierwotne zgłoszenie | · | SEC |
| Sachem Head Capital Management LP, Uncas GP LLC, Sachem Head GP LLC, Scott D. Ferguson ×2 zgłoszenia | 4 lutego 2015 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 52 insiderów · 30 dyrektorzy generalni · 21 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kristin C Peck | Chief Executive Officer | 10 lipca 2026 A | 105 068 | 0 | 2 | $-2 540 972 |
| James Saccaro | EVP, CFO & COO | 31 sierpnia 2026 A | · | 0 | 0 | $0 |
| Wetteny Joseph | Chief Financial Officer | 10 lipca 2026 A | 22 113 | 0 | 0 | $0 |
| Paul Herendeen | Exec. V.P. and CFO | 19 lipca 2016 A | · | 0 | 0 | $0 |
| Julie Fuller | Executive Vice President | 30 września 2026 M | 1 588 | 0 | 0 | $0 |
| Kevin Esch | Executive Vice President | 10 lipca 2026 A | 578 | 0 | 0 | $0 |
| Keith Sarbaugh | Executive Vice President | 10 lipca 2026 A | 3 346 | 0 | 0 | $0 |
| Rimma Driscoll | Executive Vice President | 10 lipca 2026 A | 5 715 | 0 | 0 | $0 |
| Astorga Jeannette Ferran | Executive Vice President | 10 lipca 2026 A | 1 684 | 0 | 0 | $0 |
| Abhay U Nayak | Executive Vice President | 10 lipca 2026 A | 1 965 | 0 | 0 | $0 |
| Roxanne Lagano | Executive Vice President | 10 lipca 2026 A | 15 632 | 0 | 0 | $0 |
| Jamie Brannan | Executive Vice President | 19 lutego 2026 M | 3 290 | 0 | 0 | $0 |
| Nicholas Ashton | Executive Vice President | 19 lutego 2026 M | 1 822 | 0 | 0 | $0 |
| Robert J Polzer | Executive Vice President | 10 października 2025 A | 5 120 | 0 | 0 | $0 |
| Soria Ester Banque | Executive Vice President | 4 października 2024 A | 588 | 0 | 0 | $0 |
| Wafaa Mamilli | Executive Vice President | 4 października 2024 A | 6 685 | 0 | 0 | $0 |
| Heidi C. Chen | Executive Vice President | 5 kwietnia 2024 A | 31 293 | 0 | 0 | $0 |
| Glenn David | Executive Vice President | 13 stycznia 2023 A | 46 572 | 0 | 0 | $0 |
| Timothy J Bettington | Executive Vice President | 7 października 2022 A | · | 0 | 0 | $0 |
| Roman Trawicki | Executive Vice President | 16 marca 2022 M | 8 218 | 0 | 0 | $0 |
| Catherine A. Knupp | Executive Vice President | 10 listopada 2021 S | 43 642 | 0 | 0 | $0 |
| Sherry N Pudloski | Executive Vice President | 8 października 2021 A | · | 0 | 0 | $0 |
| Robert Edward Kelly | Executive Vice President | 3 maja 2021 M | 8 300 | 0 | 0 | $0 |
| James Michael Mcfarland | Executive Vice President | 9 kwietnia 2021 A | 2 547 | 0 | 0 | $0 |
| Clinton A. Lewis Jr. | Executive Vice President | 16 grudnia 2019 M | 27 904 | 0 | 0 | $0 |
| Andrew Fenton | Executive Vice President | 6 grudnia 2019 M | 23 073 | 0 | 0 | $0 |
| Alejandro Bernal | Executive Vice President | 27 lutego 2018 M | 11 417 | 0 | 0 | $0 |
| Sandra J. Beaty | Executive Vice President | 30 kwietnia 2015 A | 6 721 | 0 | 0 | $0 |
| Joyce J. Lee | Executive Vice President | 9 kwietnia 2015 A | 3 838 | 0 | 0 | $0 |
| Stefan Weiskopf | Executive Vice President | 27 lutego 2015 A | 3 658 | 0 | 0 | $0 |
| Mark Stetter | Dyrektor | 17 września 2026 A | 1 572 | 0 | 0 | $0 |
| Frank A Damelio | Dyrektor | 7 sierpnia 2026 G | 14 808 | 1 | 0 | $501 344 |
| Michael B Mccallister | Dyrektor | 10 czerwca 2026 G | 0 | 1 | 0 | $233 280 |
| Louise M Parent | Dyrektor | 20 maja 2026 M | 28 394 | 0 | 0 | $0 |
| Paul Bisaro | Dyrektor | 13 maja 2026 P | 27 862 | 1 | 0 | $151 760 |
| Gregory Norden | Dyrektor | 9 marca 2026 G | 0 | 0 | 0 | $0 |
| Vanessa Broadhurst | Dyrektor | 19 lutego 2026 M | 3 920 | 0 | 0 | $0 |
| Antoinette Renee Leatherberry | Dyrektor | 19 lutego 2026 M | 5 280 | 0 | 0 | $0 |
| Willie M Reed | Dyrektor | 19 lutego 2026 M | 12 864 | 0 | 0 | $0 |
| Gavin Hattersley | Dyrektor | 19 lutego 2026 M | 3 354 | 0 | 0 | $0 |
| Khosla Sanjay | Dyrektor | 19 lutego 2026 A | 1 892 | 0 | 0 | $0 |
| Stephanie Tilenius | Dyrektor | 18 lutego 2026 A | · | 0 | 0 | $0 |
| Robert W Scully | Dyrektor | 21 maja 2025 M | 21 489 | 0 | 0 | $0 |
| Linda Rhodes | Dyrektor | 21 maja 2024 M | 11 192 | 0 | 0 | $0 |
| Juan Ramon Alaix | Dyrektor | 20 maja 2021 D | 215 129 | 0 | 0 | $0 |
| William C Steere JR | Dyrektor | 20 maja 2021 M | 35 074 | 0 | 0 | $0 |
| Charles H Hill | Dyrektor | 6 lutego 2013 P | 5 000 | 0 | 0 | $0 |
| Amy Schulman | Dyrektor | 6 lutego 2013 P | 5 000 | 0 | 0 | $0 |
| Douglas E. Giordano | Dyrektor | 6 lutego 2013 P | 5 000 | 0 | 0 | $0 |
| Geno J Germano | Dyrektor | 6 lutego 2013 P | 5 000 | 0 | 0 | $0 |
| Pfizer Inc. | Posiadacz 10% | 24 czerwca 2013 C | 0 | 0 | 0 | $0 |
| Richard A. Passov | · | 15 lipca 2014 A | 3 706 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 154 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IHE · iShares Trust | 3,78% | 840 871 SH | 11 września 2026 | Dziennie |
| SMRI · EA Series Trust | 1,83% | 152 486 NS | 31 lipca 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,82% | 246 575 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,56% | 196 180 SH | 2 października 2026 | Dziennie |
| CZA · Invesco Exchange-Traded Fund Trust | 1,54% | 45 027 SH | 2 października 2026 | Dziennie |
| CVAR · ETF Opportunities Trust | 1,40% | 7 761 NS | 31 lipca 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,08% | 2 889 NS | 31 lipca 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,91% | 220 756 SH | 2 października 2026 | Dziennie |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,74% | 17 243 NS | 31 lipca 2026 | N-PORT |
| IWP · iShares Trust | 0,71% | 1 867 940 SH | 11 września 2026 | Dziennie |
| COWZ · Pacer Funds Trust | 0,62% | 1 502 929 NS | 31 lipca 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,59% | 2 890 747 SH | 19 sierpnia 2026 | Dziennie |
| FLAG · Global X Funds | 0,56% | 123 NS | 31 lipca 2026 | N-PORT |
| ESLV · Strategy Shares | 0,52% | 951 NS | 31 lipca 2026 | N-PORT |
| PABU · iShares Trust | 0,51% | 174 679 SH | 11 września 2026 | Dziennie |
| IYH · iShares Trust | 0,49% | 246 300 SH | 11 września 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,47% | 200 057 NS | 31 lipca 2026 | N-PORT |
| RCGE · EA Series Trust | 0,47% | 6 141 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,45% | 1 264 118 SH | 19 sierpnia 2026 | Dziennie |
| IXJ · iShares Trust | 0,39% | 219 915 SH | 10 września 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,37% | 8 250 NS | 31 lipca 2026 | N-PORT |
| NULC · Nushares ETF Trust | 0,35% | 3 218 NS | 31 lipca 2026 | N-PORT |
| ESUM · Strategy Shares | 0,33% | 7 829 NS | 31 lipca 2026 | N-PORT |
| FQAL · FIDELITY COVINGTON TRUST | 0,31% | 57 270 NS | 31 lipca 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,31% | 10 926 000 | 2 października 2026 | Dziennie |
| SUSA · iShares Trust | 0,30% | 164 110 SH | 11 września 2026 | Dziennie |
| VFVA · VANGUARD WELLINGTON FUND | 0,29% | 33 789 SH | 19 sierpnia 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,28% | 212 600 NS | 31 lipca 2026 | N-PORT |
| SPHQ · Invesco Exchange-Traded Fund Trust | 0,28% | 754 566 SH | 2 października 2026 | Dziennie |
| VO · VANGUARD INDEX FUNDS | 0,26% | 8 177 172 SH | 19 sierpnia 2026 | Dziennie |
| EVUS · iShares Trust | 0,25% | 13 282 SH | 11 września 2026 | Dziennie |
| IMCV · iShares Trust | 0,25% | 39 931 SH | 11 września 2026 | Dziennie |
| DUHP · Dimensional ETF Trust | 0,24% | 375 907 NS | 31 lipca 2026 | N-PORT |
| QDF · FlexShares Trust | 0,23% | 67 413 NS | 31 lipca 2026 | N-PORT |
| IWR · iShares Trust | 0,23% | 1 725 551 SH | 11 września 2026 | Dziennie |
| IMCB · iShares Trust | 0,21% | 49 261 SH | 11 września 2026 | Dziennie |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 206 683 NS | 31 lipca 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,19% | 50 884 SH | 11 września 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,19% | 2 662 408 SH | 2 października 2026 | Dziennie |
| LRND · New York Life Investments ETF Trust | 0,18% | 9 465 NS | 31 lipca 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,18% | 5 589 000 | 2 października 2026 | Dziennie |
| DGRO · iShares Trust | 0,18% | 1 051 645 SH | 11 września 2026 | Dziennie |
| IMCG · iShares Trust | 0,18% | 97 153 SH | 11 września 2026 | Dziennie |
| SIZE · iShares Trust | 0,18% | 10 276 SH | 11 września 2026 | Dziennie |
| XOEF · iShares Trust | 0,17% | 526 SH | 11 września 2026 | Dziennie |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,17% | 7 884 000 | 2 października 2026 | Dziennie |
| LCOW · Pacer Funds Trust | 0,16% | 529 NS | 31 lipca 2026 | N-PORT |
| CATH · Global X Funds | 0,15% | 25 943 NS | 31 lipca 2026 | N-PORT |
| ESGU · iShares Trust | 0,15% | 364 501 SH | 10 września 2026 | Dziennie |
| ESMV · iShares Trust | 0,15% | 158 SH | 10 września 2026 | Dziennie |
| GSY · Invesco Actively Managed Exchange-T… | 0,15% | 5 769 000 | 2 października 2026 | Dziennie |
| PALC · Pacer Funds Trust | 0,15% | 3 973 NS | 31 lipca 2026 | N-PORT |
| QUAL · iShares Trust | 0,14% | 888 569 SH | 11 września 2026 | Dziennie |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,13% | 175 000 | 2 października 2026 | Dziennie |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,13% | 2 368 421 SH | 19 sierpnia 2026 | Dziennie |
| VYM · VANGUARD WHITEHALL FUNDS | 0,13% | 1 680 027 SH | 19 sierpnia 2026 | Dziennie |
| NUDV · Nushares ETF Trust | 0,13% | 834 NS | 31 lipca 2026 | N-PORT |
| USXF · iShares Trust | 0,12% | 24 978 SH | 11 września 2026 | Dziennie |
| ESG · FlexShares Trust | 0,12% | 2 010 NS | 31 lipca 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,12% | 6 837 NS | 31 lipca 2026 | N-PORT |
| PFM · Invesco Exchange-Traded Fund Trust | 0,11% | 11 940 SH | 2 października 2026 | Dziennie |
| IVE · iShares Trust | 0,10% | 695 597 SH | 11 września 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,10% | 14 085 SH | 2 października 2026 | Dziennie |
| IQSU · New York Life Investments ETF Trust | 0,10% | 4 253 NS | 31 lipca 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,10% | 3 598 101 SH | 19 sierpnia 2026 | Dziennie |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,10% | 96 479 SH | 19 sierpnia 2026 | Dziennie |
| CHRI · Global X Funds | 0,10% | 102 NS | 31 lipca 2026 | N-PORT |
| LGDX · Tidal Trust III | 0,10% | 1 814 NS | 31 lipca 2026 | N-PORT |
| IUSV · iShares Trust | 0,10% | 368 059 SH | 11 września 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,09% | 3 986 NS | 31 lipca 2026 | N-PORT |
| SUSL · iShares Trust | 0,09% | 14 854 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 10 375 SH | 2 października 2026 | Dziennie |
| DSI · iShares Trust | 0,09% | 64 531 SH | 11 września 2026 | Dziennie |
| HAPI · Harbor ETF Trust | 0,08% | 5 320 NS | 31 lipca 2026 | N-PORT |
| AQLT · iShares Trust | 0,08% | 3 693 SH | 10 września 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,08% | 55 415 SH | 2 października 2026 | Dziennie |
| WRND · New York Life Investments ETF Trust | 0,08% | 109 NS | 31 lipca 2026 | N-PORT |
| MPLY · Strategy Shares | 0,08% | 158 NS | 31 lipca 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,08% | 5 377 NS | 31 lipca 2026 | N-PORT |
| ESGG · FlexShares Trust | 0,07% | 1 064 NS | 31 lipca 2026 | N-PORT |
| EGLE · Global X Funds | 0,07% | 21 NS | 31 lipca 2026 | N-PORT |
| IWF · iShares Trust | 0,07% | 1 245 265 SH | 11 września 2026 | Dziennie |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 521 663 SH | 19 sierpnia 2026 | Dziennie |
| IWS · iShares Trust | 0,06% | 135 157 SH | 11 września 2026 | Dziennie |
| PRF · Invesco Exchange-Traded Fund Trust | 0,06% | 85 655 SH | 2 października 2026 | Dziennie |
| CRBN · iShares Trust | 0,06% | 9 378 SH | 10 września 2026 | Dziennie |
| TOPC · iShares Trust | 0,06% | 258 SH | 11 września 2026 | Dziennie |
| ACVF · ETF Opportunities Trust | 0,06% | 1 125 NS | 31 lipca 2026 | N-PORT |
| USCL · iShares Trust | 0,06% | 22 073 SH | 10 września 2026 | Dziennie |
| HQGO · Lattice Strategies Trust | 0,06% | 354 NS | 31 lipca 2026 | N-PORT |
| XTR · Global X Funds | 0,05% | 34 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,05% | 452 NS | 31 lipca 2026 | N-PORT |
| XRMI · Global X Funds | 0,05% | 344 NS | 31 lipca 2026 | N-PORT |
| XVV · iShares Trust | 0,05% | 4 833 SH | 10 września 2026 | Dziennie |
| XCLR · Global X Funds | 0,05% | 24 NS | 31 lipca 2026 | N-PORT |
| ILCV · iShares Trust | 0,05% | 9 460 SH | 11 września 2026 | Dziennie |
| PTLC · Pacer Funds Trust | 0,05% | 21 352 NS | 31 lipca 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,05% | 57 993 NS | 31 lipca 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,05% | 7 112 NS | 31 lipca 2026 | N-PORT |
| XYLD · Global X Funds | 0,05% | 21 020 NS | 31 lipca 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,05% | 10 888 932 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,05% | 95 134 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,05% | 1 758 NS | 31 lipca 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,05% | 34 718 NS | 31 lipca 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,05% | 36 NS | 31 lipca 2026 | N-PORT |
| IVV · iShares Trust | 0,05% | 5 283 923 SH | 11 września 2026 | Dziennie |
| ILCB · iShares Trust | 0,05% | 8 221 SH | 9 września 2026 | Dziennie |
| SPUU · Direxion Shares ETF Trust | 0,05% | 1 582 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,05% | 64 661 SH | 2 października 2026 | Dziennie |
| QDPL · Pacer Funds Trust | 0,05% | 10 102 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,04% | 70 832 NS | 31 lipca 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,04% | 72 658 SH | 2 października 2026 | Dziennie |
| PBP · Invesco Exchange-Traded Fund Trust | 0,04% | 2 457 SH | 2 października 2026 | Dziennie |
| IYY · iShares Trust | 0,04% | 18 056 SH | 10 września 2026 | Dziennie |
| IWB · iShares Trust | 0,04% | 290 521 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,04% | 115 640 SH | 10 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,04% | 544 118 SH | 11 września 2026 | Dziennie |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,04% | 9 810 SH | 2 października 2026 | Dziennie |
| ILCG · iShares Trust | 0,04% | 17 162 SH | 11 września 2026 | Dziennie |
| VV · VANGUARD INDEX FUNDS | 0,04% | 440 643 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,04% | 11 984 400 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,04% | 69 366 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,04% | 35 465 SH | 19 sierpnia 2026 | Dziennie |
| HCMT · Direxion Shares ETF Trust | 0,04% | 2 917 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,04% | 17 007 NS | 31 lipca 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,04% | 32 772 NS | 31 lipca 2026 | N-PORT |
| TOK · iShares Trust | 0,04% | 1 209 SH | 11 września 2026 | Dziennie |
| PHDG · Invesco Actively Managed Exchange-T… | 0,04% | 325 SH | 2 października 2026 | Dziennie |
| URTH · iShares, Inc. | 0,03% | 37 976 SH | 10 września 2026 | Dziennie |
| DFSU · Dimensional ETF Trust | 0,03% | 9 950 NS | 31 lipca 2026 | N-PORT |
| ACWI · iShares Trust | 0,03% | 138 514 SH | 9 września 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,03% | 356 907 SH | 19 sierpnia 2026 | Dziennie |
| TILT · FlexShares Trust | 0,03% | 8 216 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,03% | 69 465 NS | 31 lipca 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,02% | 2 228 NS | 31 lipca 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,02% | 5 737 NS | 31 lipca 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 54 015 SH | 19 sierpnia 2026 | Dziennie |
| IWD · iShares Trust | 0,02% | 198 738 SH | 11 września 2026 | Dziennie |
| QDEF · FlexShares Trust | 0,02% | 1 148 NS | 31 lipca 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,00% | 3 000 | 30 września 2026 | Dziennie |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 66 000 | 2 października 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,00% | 6 792 NS | 31 lipca 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| VCEB · VANGUARD WORLD FUND | · | · | 30 lipca 2026 | Dziennie |
ZTS Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 24 analityków
KUP
Średni cel
$89.50
+28,4%
4 16,7%
Mocne kupno
8 33,3%
Kup
12 50,0%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
14 analityków · 2026-09-28Średnia cel $96.00 +37,8%
← Poniżej wszystkich celów
Aktualna cena $69.69
Niski$80.00
Średnia$96.00
Wysoki$155.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | · |
| JNJ | · | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | · | 14.5 | 1.3% | 28.1% | 36.9% | · |
| PFE | · | 18.3 | -1.7% | 12.4% | 8.9% | · |
| BMY | · | 15.6 | -0.22% | 14.6% | 40.5% | · |
| RPRX | · | 21.7 | 5.1% | 32.4% | 8.0% | · |
| VTRS | · | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | · |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Zoetis Stock: Szacunki i Oceny Analityków
Yahoo Finance · 4 miesiące, 2 tygodnie temu
Ten akcja związana ze zdrowiem zwierząt notuje swój najniższy w historii wskaźnik P/E.
Nasdaq · 5 miesięcy, 1 tydzień temu
2 Akcje Spółek ds. Ochrony Zdrowia do Kupienia i 1, do Której Należy Podchodzić z Ostrożnością
Nasdaq · 5 miesięcy, 2 tygodnie temu
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 6, 2026